Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Medpace Holdings Inc Market Cap
The Medpace Holdings Inc (MEDP) share price is expected to decrease by 2.46% over the next year. This is based on calculating the average 12-month share price estimate provided by 2 stock analysts who have covered MEDP. Price targets range from $312.00 at the low end to $452.00 at the high end. The current analyst consensus for MEDP is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
MEDP is a stock in Health Care which has been forecasted to be worth $382.00 as an average. On the higher end, the forecast price is $452.00 USD by john sourbeer from UBS and on the lower end MEDP is forecasted to be $312.00 by from .
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| john sourbeer UBS | Buy | $452.0 | upgraded | Feb 15, 2024 |
| eric coldwell Robert W. Baird | Buy | $408.0 | reiterated | Feb 13, 2024 |
| david windley Jefferies | Hold | $281.0 | maintained | Oct 25, 2023 |
| sandy draper Guggenheim | Buy | $252.0 | upgraded | May 8, 2023 |
| john kreger William Blair | Buy | None | maintained | Oct 19, 2021 |
| erin wright Morgan Stanley | Buy | $205.0 | maintained | Jul 20, 2021 |
| steve baxter Wells Fargo | Hold | $91.0 | downgraded | May 13, 2020 |
| ryan daniels William Blair | Buy | None | reiterated | Aug 17, 2018 |
| jason twizell MUFG Securities Americas Inc | Hold | $40.0 | initiatedcoverage | Apr 20, 2018 |
| donald hooker KeyBanc | Hold | None | downgraded | Jul 10, 2017 |
| jon groberg UBS | Buy | $35.0 | initiatedcoverage | Sep 6, 2016 |
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
When did it IPO
2016
Staff Count
5,900
Country
United States
Sector/Industry
Healthcare/Diagnostics & Research
CEO
Dr. August James Troendle M.D.
Market Cap
$12.05B
In 2023, MEDP generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that MEDP's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
$45.45
KRTX-USD
$318.08
HOOD-USD
$14.09
MSTR-USD
$699.56
LNT-USD
$48.35
MORN-USD
$273.91
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
